As it is an established practice to treat NSCLC patients with EGFR TKIs and there increasing evidence that FAK plays a major role in lung cancer growth and progression, we set out to test the utility of combining the EGFR inhibitor erlotinib with FAK inhibition in NSCLC. The gene discussed is PTK2; the disease is lung cancer.